Biological
Markers
Biological markers in schizotypal and
borderline personality disorders
Encephale 2000
Nov-Dec;26(6):42-54 (Article in French)
Ajamieh A,
Ansseau M.
Service de Psychiatrie et de Psychologie
Medicale, CHU du Sart Tilman, B-4000 Liege,
Belgique.
"A preliminary but growing body of
evidence supports the existence of biological substrates in
personality disorders. Based on a review of the literature, the
article deals with the major biological markers: genetic,
cognitive, biochemical, electrophysiological and organic markers,
of schizotypal and borderline personality disorders. In addition,
the article compares these findings in these two types of
pathological personality. In the field of genetics, we notice
several indices in favour of a relationship between schizotypal
personality disorder (SPD) and chronic schizophrenia. In contrast,
in borderline personality disorder (BPD), indices were lacking for
such a relationship between this disorder and one of the axis I
diagnosis, or a clear genetic transmission. In the field of
cognitive tests, we can note in both SPD and BPD, that the
abnormalities which would be at the level of temporal and frontal
lobes, may be implicated in the observable cognitive troubles in
these two disorders. In the field of neurobiochemistry, the
dopaminergic and serotonergic systems seem to be implicated in the
etiology of SPD while several data point out the fact that several
neurotransmitter systems (dopaminergic, serotonergic,
noradrenergic and cholinergic) seem to be involved in the etiology
of BPD. Finally, in the field of electrophysiology, we notice that
some of these tests observed in SPD (smooth pursuit eye movements,
evoked potentials, modification of the electrodermic response)
seem reinforcing the relationship between SPD and schizophrenia
while those observed in BPD seem reinforcing either a relationship
between BPD and depression (sleep studies), or a relationship
between BPD and schizophrenia (evoked potentials, smooth pursuit
eye movements)."
Pharmacological
Treatment
Depakote
J Clin Psychiatry 2001
Mar;62(3):199-203
Hollander E, Allen A, Lopez RP,
Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein
DJ.
Department of Psychiatry, Mount Sinai School of
Medicine, New York, NY 10029-6574, USA.
Depakote was compared to placebo in 16
borderline patients. 12 were given Depakote and 4 were given a
placebo. "Treatment with divalproex sodium may be more
effective than placebo for global symptomatology, level of
functioning, aggression, and depression."
Treatment with Psychotropic
Medication
Tidsskr Nor Laegeforen 2000 Aug
10;120(18):2135-41
Nissen T. Psykiatrisk senter for Tromso
og Karlsoy Regionsykehuset i Tromso. (Article in
Norwegian)
"Neuroleptics have a modest, but broad
therapeutic effect on symptoms in all domains. Doses are lower
than those used for treating schizophrenia. Antidepressants have a
more inconsistent effect. Tricyclics have been the least
successful, whereas irreversible MAO inhibitors and selective
serotonin reuptake inhibitors (SSRIs) have been effective in
treating mood symptoms and impulsivity. Lithium has a possible
effect in diminishing anger and suicidal symptoms.
As there is no "drug of choice" for the
treatment of borderline personality disorder, a more rational
clinical approach might be to treat different symptom clusters
(cognitive/schizotypal, affective, impulsive) rather than the
disorder itself."
Zyprexa
Biol Psychiatry 1999 Nov
15;46(10):1429-35
Schulz SC, Camlin KL, Berry SA,
Jesberger JA.
Department of Psychiatry, University of
Minnesota Medical School, Minneapolis 55454-1495, USA.
Open-label pilot study where borderlines
treated with Zyprexa "showed statistically significant reduction
in self-rated and clinician-rated scales. Symptoms associated with
BPD and dysthymia were among those to be substantially reduced.
Further studies to explore olanzapine's efficacy versus placebo,
as well as comparison to other potential treatments for BPD, are
important next steps."
Naltrexone in the treatment of
dissociative symptoms in patients with borderline personality
disorder: an open-label trial.
J Clin Psychiatry 1999
Sep;60(9):598-603
Bohus MJ, Landwehrmeyer GB, Stiglmayr
CE, Limberger MF, Bohme R, Schmahl CG.
Department of
Psychiatry, University of Freiburg, Freiburg im Breisgau,
Germany.
BPD and PTSD consumers many times
experience dissociative symptoms, including flashbacks. Female BPD
patients were treated with naltrexone, an opiate antagonist; 25 to
100 mg three times a day., for at least 2 weeks. The "scores
reflected a highly significant reduction of the duration and the
intensity of dissociative phenomena and tonic immobility as well
as a marked reduction in analgesia during treatment with
naltrexone. Six of 9 patients reported a decrease in the mean
number of flashbacks per day.
CONCLUSION: These observations support
the hypothesis that an increased activity of the opioid system
contributes to dissociative symptoms, including flashbacks, in
borderline personality disorder and suggest that these symptoms
may respond to treatment with opiate antagonists."
Effectiveness of partial
hospitalization in the treatment of borderline personality
disorder: a randomized controlled trial.
Am J Psychiatry 1999
Oct;156(10):1563-9
Bateman A, Fonagy P.
Halliwick
Day Unit, St. Ann's Hospital.
"Psychoanalytically oriented partial
hospitalization is superior to standard psychiatric care for
patients with borderline personality disorder. Replication is
needed with larger groups, but these results suggest that partial
hospitalization may offer an alternative to inpatient
treatment."